The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer.
 
Hans J. Hammers
Consulting or Advisory Role - Bristol-Myers Squibb; exelixis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; Janssen Oncology; Merck; NexImmune; Pfizer; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Castle Biosciences
Travel, Accommodations, Expenses - Newlink Genetics
 
Eugene Paul Kennedy
Employment - CSL Limited (I); Newlink Genetics
Stock and Other Ownership Interests - Newlink Genetics
 
Nicholas N. Vahanian
Employment - Newlink Genetics
Leadership - Newlink Genetics
Stock and Other Ownership Interests - Newlink Genetics
 
Charles J. Link
Employment - Newlink Genetics
Leadership - Newlink Genetics
Stock and Other Ownership Interests - Newlink Genetics
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)